uniQure N.V.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a QURE research report →
Range $28 – $80
Price Chart
About the company
uniQure N. V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
- CEO
- Matthew C. Kapusta
- IPO
- 2014
- Employees
- 221
- HQ
- Amsterdam, NH, NL
Get TickerSpark's AI analysis on QURE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.36B
- P/E
- -5.87
- Fwd P/E
- 17.63
- PEG
- -0.41
- P/S
- 72.27
- P/B
- 4.93
- EV/EBITDA
- -8.36
- Div Yield
- 0.00%
- Gross Margin
- 29.32%
- Op Margin
- -1017.97%
- Net Margin
- -1154.84%
- ROE
- -96.34%
- ROIC
- -23.15%
Latest fiscal year · YoY change
- Revenue
- $16.10M-40.6%
- Gross Profit
- $14.41M+63.9%
- Op Income
- $-187,827,000
- Net Income
- $-198,971,000+16.9%
- EPS
- $-3.46+29.7%
- OCF Growth
- +2.6%
- FCF Growth
- +4.1%
- 52W High
- $51.72
- 52W Low
- $8.73
- 50D MA
- $27.55
- 200D MA
- $29.55
- Beta
- 0.94
- RSI (14)
- 33
- Avg Volume
- 2.24M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
uniQure said AMT-130’s FDA filing is under priority review, the confirmatory study is being readied, and the company expects cash runway into 2030 as it prepares for a possible 2027 U.S. launch.· November 4, 2026
- FDA accepted the AMT-130 BLA and granted priority review, with a PDUFA date of May 1, 2027; the U.K. MHRA also validated the MAA.
- Management highlighted September data showing 75% slowing on cUHDRS and 60% slowing on TFC in the high-dose group versus external controls, both statistically significant.
- The planned confirmatory study will be randomized 2:1, include about 200 patients, use TFC at 36 months as the primary endpoint, and screening is expected to start by year-end.
- Commercial prep is underway for a potential 2027 launch, with center readiness, neurosurgical training, payer engagement, and team buildout all in progress.
- Cash, cash equivalents and investment securities were $768.4 million at September 30, 2026, and management said that is enough to fund operations into 2030.
Revenue for the third quarter of 2026 was $5.2 million, up from $3.7 million in the same period of 2025. Research and development expense was $35.5 million versus $34.4 million a year ago, and selling, general and administrative expense was $23.9 million versus $19.4 million a year ago. Cash, cash equivalents and investment securities were $768.4 million at September 30, 2026, compared with $622.5 million at December 31, 2025. Forward-looking, the company said AMT-130 is under priority review with a May 1, 2027 PDUFA date, expects the confirmatory study to enroll about 200 patients and begin screening by year-end, and expects cash to fund operations into 2030.
Matt Kapusta framed the quarter as a major step forward for Huntington’s disease, emphasizing that the BLA acceptance and U.K. filing bring patients closer to a treatment option. He repeatedly pointed to the company’s belief that AMT-130 has shown meaningful disease slowing and said uniQure is focused on working with regulators, getting the confirmatory study underway, and preparing for a U.S. launch in 2027. His tone was confident and urgent, but measured around the regulatory process.
Christian Klemt highlighted a revenue increase to $5.2 million, driven by higher license revenue, while R&D rose modestly to $35.5 million due mainly to higher employee and contractor costs, offset partly by lower direct R&D spend tied to AMT-130 process validation. SG&A increased to $23.9 million because of launch preparation, hiring, professional fees, and IT costs to support potential commercial launches. He said cash, cash equivalents and investment securities of $768.4 million should be sufficient to fund operations into 2030.
Analysts focused on launch readiness, the confirmatory study, and regulatory risk. Management said the study is designed to reduce dropout risk by being global and including countries where AMT-130 will not be commercially available during the trial; they also said the sample size was adjusted for dropout assumptions and that the company expects a day 120 safety update. On launch, they said capacity will be the main early constraint, with site readiness, P&T approvals, and payer access shaping uptake; they estimated the initial footprint would be north of 15 centers, though the exact number is not yet set.
The biggest bull case on this call is that uniQure now has an accepted BLA with priority review, plus validated U.K. filing, which materially de-risks the regulatory path. Management also presented additional long-term data they believe support a meaningful functional benefit, and the company has substantial cash to carry it through launch preparation and the confirmatory study.
The main risks are regulatory: the FDA could still ask for additional information, an AdCom could be scheduled, or a major amendment could delay the PDUFA if the agency requests more long-term data. Commercially, launch capacity is still uncertain, early uptake may be limited by center readiness and reimbursement processes, and the confirmatory study itself still needs to be executed on time with potential dropout and enrollment challenges.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 83.1%
- Shares Outstanding
- 70.14M
- Float Shares
- 58.29M
of shares held by institutions
304 13F filers
Buy/sell ratio 0.57. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Avoro Capital Advisors LLC | 6.73M | ▲ 768.18K |
| Jpmorgan Chase & Co | 5.95M | ▲ 1.08M |
| Rtw Investments, LP | 3.94M | ▲ 1.36M |
| State Street Corp | 2.58M | ▼ 320.17K |
| Blackrock, Inc. | 2.11M | ▲ 231.83K |
| Morgan Stanley | 1.93M | ▲ 867.30K |
| Aberdeen Group PLC | 1.92M | ▼ 932.89K |
| Orbimed Advisors LLC | 1.81M | ▼ 328.66K |
| Jennison Associates LLC | 1.56M | ▲ 327.62K |
| Boxer Capital Management, LLC | 1.50M | ▲ 841.30K |
| Goldman Sachs Group Inc | 1.48M | ▲ 212.72K |
| Two Sigma Investments, LP | 1.46M | ▼ 1.21M |
Held by 115 ETFs
Biggest fund positions in QURE by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 6, 26 | Meek David D. | sell | 9,080 |
| Oct 30, 26 | Abi-Saab Walid | other | 18,750 |
| Jul 2, 26 | Kapusta Matthew C | other | 21,082 |
| Jul 2, 26 | Kapusta Matthew C | sell | 9,200 |
| Jul 2, 26 | Kapusta Matthew C | sell | 4,282 |
| Jul 2, 26 | Kapusta Matthew C | sell | 7,600 |
| Jul 2, 26 | Kapusta Matthew C | other | 21,082 |
| Jun 30, 26 | Abi-Saab Walid | other | 10,000 |
| Jun 30, 26 | Abi-Saab Walid | sell | 10,000 |
| Jun 30, 26 | Abi-Saab Walid | sell | 20,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our QURE coverage
Recent articles, reports, and earnings notes.
Want a deeper read on QURE?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
uniQure: A Breakthrough In Huntington's, With A Market Too Large To Ignore
seekingalpha.com · Nov 14
uniQure CEO Defends Huntington's Therapy Data, Sees Opportunity Ahead of FDA Decision
marketbeat.com · Nov 13
QURE Stock Rallies 17.5% in a Month: What Should Investors Do Now?
zacks.com · Nov 13
uniQure Prepares for Potential FDA Panel on Huntington's Gene Therapy After Priority Review Nod
marketbeat.com · Nov 13
uniQure Q3 Earnings Call Highlights
marketbeat.com · Nov 4
uniQure N.V. (QURE) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 4
uniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates
zacks.com · Nov 4
uniQure Announces Third Quarter 2026 Financial Results and Provides Company Update
globenewswire.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
